These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20723006)

  • 1. Anti-ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non-diabetic rat hearts.
    Calderone V; Testai L; Martelli A; La Motta C; Sartini S; Da Settimo F; Breschi MC
    J Pharm Pharmacol; 2010 Jan; 62(1):107-13. PubMed ID: 20723006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
    Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
    Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The absence of synergism between the effects of an aldose reductase inhibitor, epalrestat, and a vasodilator, cilostazol, on the nerve conduction slowing and the myelinated fiber atrophy in streptozotocin-induced diabetic rats.
    Sasaki H; Naka K; Kishi Y; Furuta M; Sanke T; Mukoyama M; Nanjo K
    Exp Neurol; 1997 Aug; 146(2):466-70. PubMed ID: 9270057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (2-Benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)-acetic acid: an aldose reductase inhibitor and antioxidant of zwitterionic nature.
    Stefek M; Tsantili-Kakoulidou A; Milackova I; Juskova M; Snirc V; Triantos N
    Bioorg Med Chem; 2011 Dec; 19(23):7181-5. PubMed ID: 22037047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Inhibition effect of epalrestat on rat lens osmotic expansion].
    Ji LX; Shen N; Li CN; Liu Q; Huan Y; Shen ZF
    Yao Xue Xue Bao; 2009 Oct; 44(10):1107-11. PubMed ID: 20055132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling.
    Gu J; Wang JJ; Yan J; Cui CF; Wu WH; Li L; Wang ZS; Yu M; Gao N; Liu L; Ouyang DS
    J Ethnopharmacol; 2011 Jan; 133(1):6-13. PubMed ID: 20817083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of sorbitol pathway and treatment effect of aldose reductase inhibitor ONO2235 in the up-regulation of cardiac M2-muscarinic receptors in streptozotocin-induced diabetic rats.
    Liu TP; Juang SW; Cheng JT; Tong YC
    Neurosci Lett; 2005 Jul 22-29; 383(1-2):131-5. PubMed ID: 15936525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldose reductase inhibitor ONO-2235 restores the alterations of bladder nerve growth factor and neurotrophin receptor p75 genetic expression in streptozotocin induced diabetic rats.
    Tong YC; Cheng JT
    J Urol; 2007 Nov; 178(5):2203-7. PubMed ID: 17870109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of an aldose reductase inhibitor on altered sympathetic nerve responsiveness of isolated right atria in diabetic rats.
    Sato N; Hashimoto H; Takiguchi Y; Nakashima M
    Arzneimittelforschung; 1990 Jul; 40(7):763-6. PubMed ID: 2121149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a new aldose reductase inhibitor on various tissues in vitro.
    Terashima H; Hama K; Yamamoto R; Tsuboshima M; Kikkawa R; Hatanaka I; Shigeta Y
    J Pharmacol Exp Ther; 1984 Apr; 229(1):226-30. PubMed ID: 6423811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review.
    Schemmel KE; Padiyara RS; D'Souza JJ
    J Diabetes Complications; 2010; 24(5):354-60. PubMed ID: 19748287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of an aldose reductase inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats.
    Hashimoto H; Satoh N; Takiguchi Y; Nakashima M
    J Pharmacol Exp Ther; 1990 May; 253(2):552-7. PubMed ID: 2159998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of aldose reductase inhibitor on retinal microangiopathy in streptozotocin-diabetic rats.
    Kojima K; Matsubara H; Harada T; Mizuno K; Suzuki M; Hotta N; Kakuta H; Sakamoto N
    Jpn J Ophthalmol; 1985; 29(1):99-109. PubMed ID: 3159927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
    Kashima K; Sato N; Sato K; Shimizu H; Mori M
    Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of propionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor.
    Hotta N; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K; Naruse K; Nakashima E; Sakamoto N
    J Pharmacol Exp Ther; 1996 Jan; 276(1):49-55. PubMed ID: 8558455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dual-acting aldose reductase inhibitor impedes oxidative and carbonyl stress in tissues of fructose- and streptozotocin-induced rats: comparison with antioxidant stobadine.
    Kaya A; Ceylan AF; Kavutcu M; Santamaria A; Šoltésová Prnová M; Stefek M; Karasu Ç
    Drug Chem Toxicol; 2024 Sep; 47(5):710-720. PubMed ID: 37795621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
    Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
    Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA; Borja NL
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
    Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
    Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.